| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
Departments of Cancer Biology and Public Health Sciences Comprehensive Cancer Center of W ake Forest University Winston-Salem, North Carolina 27157
Department of Urology University of Miami School of Medicine Miami, Florida 33101
Department of Molecular and Cellular Pharmacology University of Miami School of Medicine Miami, Florida 33101
Letter
We read with interest the report by Blutt et al. (1) , demonstrating inhibition of the growth of LNCaP prostate cancer cells in vivo by the calcitriol analogue, EB1089. We reported previously significant inhibitory effects of EB1089 on the proliferation of prostate cancer cells in vivo in the Dunning MAT LyLu prostate cancer model, a model of androgen-insensitive, metastatic prostate cancer. In addition, we showed that EB1089 significantly inhibits prostate cancer metastasis, the primary cause of death in men with prostate cancer, and that this effect can be achieved without inducing cachexia or unacceptable levels of hypercalcemia (2) . The report by Blutt et al. is consistent with the hypothesis that vitamin D plays an important role in the natural history of prostate cancer (3) and, with our findings that less calcemic analogues of calcitriol, such as EB1089, hold promise as therapeutic agents (4) .
Received 3/ 6/00. Accepted 3/16/01.
REFERENCES
Department of Molecular and Cellular Biology Baylor College of Medicine Houston, Texas 77030
Lokeshwar et al. (1)
have made the interesting finding that although the growth of MAT LyLu tumors was minimally affected by EB1089 treatment, tumor metastasis to the lung was reduced. Their finding that the MAT LyLu cells had undetectable levels of functional vitamin D receptors suggests that there may be systemic effects of EB1089 on tumor metastasis. However, the results of these experiments should be interpreted with caution because the EB1089 treatment caused a 19% elevation of serum calcium to a clinically unacceptable level (
12.7 mg/dl). Nonetheless, both the Lokeshwar study (1)
and our study (2)
suggest that EB1089 or other less calcemic analogues are promising candidates for the treatment of prostate cancer.
REFERENCES
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |